ArticleBritish journal of cancer2013
Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis.
Article in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Noggin Promotes Cell Proliferation Through Up-regulating EGFR/HER2 in Pancreatic Cancer Cells.Cancer genomics & proteomics · 2025Article
- Loss of tumor-derived SMAD4 enhances primary tumor growth but not metastasis following BMP4 signalling.Cell communication and signaling : CCS · 2024Article
- Engineering of a Microscale Niche for Pancreatic Tumor Cells Using Bioactive Film Coatings Combined with 3D-Architectured Scaffolds.ACS applied materials & interfaces · 2022Article
- The Role ofCancers · 2022Review
- Article
- Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer.Oncogene · 2020Article
- Bone morphogenetic protein receptor signal transduction in human disease.The Journal of pathology · 2019Review
- Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors.Oncotarget · 2016Article
- Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.Biochemical Society transactions · 2016Review
- Bone Morphogenetic Proteins.Cold Spring Harbor perspectives in biology · 2016Review
- Article
- Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis.Translational oncology · 2016Article
- The soluble form of BMPRIB is a novel therapeutic candidate for treating bone related disorders.Scientific reports · 2016Article
- Activin receptor-like kinases: a diverse family playing an important role in cancer.American journal of cancer research · 2016Review
- Article
- The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC.British journal of cancer · 2015Article
- SMAD4 and its role in pancreatic cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression of SMAD4, the central component of the transforming growth factor-β (TGF-β) and bone morphogenetic protein (BMP) signalling pathways, is lost in 50% of pancreatic cancers and is associated with a poor survival. Although the TGF-β pathway has been extensively studied and characterised in pancreatic cancer, there is very limited data on BMP signalling, a well-known tumour-suppressor pathway. BMP signalling can be lost not only at the level of SMAD4 but also at the level of BMP receptors (BMPRs), as has been described in colorectal cancer.
methodsWe performed immunohistochemical analysis of the expression levels of BMP signalling components in pancreatic cancer and correlated these with survival. We also manipulated the activity of BMP signalling in vitro.
resultsReduced expression of BMPRIA is associated with a significantly worse survival, primarily in a subset of SMAD4-positive cancers. In vitro inactivation of SMAD4-dependent BMP signalling increases proliferation and invasion of pancreatic cancer cells, whereas inactivation of BMP signalling in SMAD4-negative cells does not change the proliferation and invasion or leads to an opposite effect.
conclusionOur data suggest that BMPRIA expression is a good prognostic marker and that the BMP pathway is a potential target for future therapeutic interventions in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.